ReviewFrontiers in immunology2020
Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.Life science alliance · 2022Trial
- RedefiningMolecular therapy. Nucleic acids · 2025Article
- Novel Advancements in COVID-19 and Neuroscience.Journal of personalized medicine · 2024Article
- Drug Synergism of Anticancer Action in Combination with Favipiravir and Paclitaxel on Neuroblastoma Cells.Medicina (Kaunas, Lithuania) · 2023Article
- microRNA-185 Inhibits SARS-CoV-2 Infection through the Modulation of the Host's Lipid Microenvironment.Viruses · 2023Article
- Recent updates on liposomal formulations for detection, prevention and treatment of coronavirus disease (COVID-19).International journal of pharmaceutics · 2023Review
- A computational study on the molecular mechanisms of panduratin A as a potential inhibitor on SARS-CoV-2 protein targets.Heliyon · 2023Article
- Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein.Journal of medicinal chemistry · 2022Article
- Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England.ClinicoEconomics and outcomes research : CEOR · 2022Article
- Monoclonal antibody therapies in the management of SARS-CoV-2 infection.Expert opinion on investigational drugs · 2022Article
- 2-Phenoxyacetamide derivatives as SARS-CoV-2 main protease inhibitor: In silico studies.Results in chemistry · 2022Article
- Pandemic strategies with computational and structural biology against COVID-19: A retrospective.Computational and structural biotechnology journal · 2022Review
- Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview.Vaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
By December 2020, the COVID-19 pandemic had caused more than 74 million confirmed cases and 1.6 million related deaths around the world. However, only a few drugs have been approved in certain areas and for use in conditional patients, and the vaccine candidates were only recently approved or authorized for emergency use without being fully implemented worldwide, suggesting that we are yet to reach effective control of the current outbreak as its uninhibited transmission continues precariously. Over the past few months, several therapeutic candidates have been proven ineffective in large clinical trials, while some other agents exhibited promising preliminary results. Meanwhile, the investigation of SARS-CoV-2-specific antivirals is underway. Despite still being preclinical, these agents could be beneficial for the long-term control of COVID-19 and deserve more research focus. In this article, we update the current status of therapeutic candidates that have been examined for COVID-19 management, including the virus-targeting inhibitors and host-targeting agents, with their antiviral efficacy
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.